{"id":55812,"date":"2026-01-29T20:57:29","date_gmt":"2026-01-29T12:57:29","guid":{"rendered":"https:\/\/flcube.com\/?p=55812"},"modified":"2026-01-29T20:57:31","modified_gmt":"2026-01-29T12:57:31","slug":"neushen-therapeutics-raises-series-a-for-cns-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55812","title":{"rendered":"NeuShen Therapeutics Raises Series A+ for CNS Drug Development"},"content":{"rendered":"\n

NeuShen Therapeutics<\/strong>, a Sino\u2011US biotech focused on central nervous system (CNS) disorders, announced the completion of its Series A+ financing round<\/strong>, raising tens of millions of US dollars<\/strong>. The round was led by Lilly Asia Ventures<\/strong>, with Pivotal BioVenture Partners<\/strong> participating as co\u2011investor. Existing shareholders Shanghai Healthcare Capital, Lapam Capital, and TTM Capital<\/strong> continued their support.<\/p>\n\n\n\n

Financing Structure & Strategic Terms<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>NeuShen Therapeutics (Sino\u2011US)<\/td><\/tr>
Financing Round<\/strong><\/td>Series A+<\/td><\/tr>
Amount Raised<\/strong><\/td>Tens of millions of US dollars<\/td><\/tr>
Lead Investor<\/strong><\/td>Lilly Asia Ventures<\/td><\/tr>
Co\u2011Investor<\/strong><\/td>Pivotal BioVenture Partners<\/td><\/tr>
Existing Shareholders<\/strong><\/td>Shanghai Healthcare Capital, Lapam Capital, TTM Capital<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Advance preclinical research and clinical trials for CNS drug pipeline<\/td><\/tr>
Focus Areas<\/strong><\/td>Psychiatric disorders and neurodegenerative diseases<\/td><\/tr>
Development Stage<\/strong><\/td>Preclinical\u2011stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Implications<\/h2>\n\n\n\n